6533b7d2fe1ef96bd125f55f

RESEARCH PRODUCT

Validity and reliability of the Migraine-Treatment Optimization Questionnaire.

Kenneth S. AlbertMarcelo E. BigalMiguel J. A. LáinezN IslamBruce ParsonsA. GendollaD ValadeJulio PascualG. BussoneRichard B. LiptonK. Kolodner

subject

AdultMalemedicine.medical_specialtyMigraine DisordersValidityDisability EvaluationQuality of lifeCronbach's alphaSurveys and QuestionnairesOutcome Assessment Health CareMedicineHumansMigraine treatmentAgedbusiness.industryConstruct validityReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseaseTolerabilityMigrainePhysical therapyQuality of LifeInternational Classification of Headache DisordersFemaleNeurology (clinical)businessClinical psychology

description

Our aim was to establish the validity and reliability of a patient-rated Migraine Treatment Optimization Questionnaire (M-TOQ in primary care. Patients who met International Classification of Headache Disorders, 2nd edn criteria for migraine completed a 19-item questionnaire containing candidate items for the M-TOQ and three questionnaires designed to test convergent/construct validity [Migraine Disability Assessment Scale (MIDAS), Headache Impact Test (HIT)-6 and Migraine-Specific Quality of Life Scale (MSSQoL)]. A 15-item (M-TOQ15) and a five-item (M-TOQ-5) questionnaire were derived. Two hundred and fifty-three adult patients were recruited. Five treatment optimization domains were identified: functioning, rapid relief, consistency of relief, risk of recurrence and tolerability; with Cronbach alphas of 0.70-0.84. The Cronbach α for M-TOQ-15 was 0.85, and it correlated well with MIDAS, HIT-6 and MSQoL (r = 0.33-0.44). The Cronbach α for M-TOQ-5 was 0.66, and it also correlated well with the three questionnaires (r = 0.33-0.41). The utility of the M-TOQ for assessing treatment benefit in research (M-TOQ-5) and primary care (M-TOQ-5) should be further validated.

10.1111/j.1468-2982.2008.01786.xhttps://pubmed.ncbi.nlm.nih.gov/19239676